RxDoctor Payments Data

Mark Lensky, MD

Clinical Cardiac Electrophysiology · Los Angeles, CANPI 1558582866

Payments from drug & device makers

$12,265in general payments, 2019–2025

Across 91 payments — averaging $134.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$12K
  • Gilead$134
  • Medtronic$76
  • Novartis$75
  • Amgen$68
  • Pfizer$49
  • plus $24 from 1 others

What the payments were for

  • Consulting fees$8,51569%
  • Travel & lodging$9518%
  • Food & beverage$2,79923%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott65$11,839
Gilead12$134
Medtronic(2 entities)3$76
Novartis4$75
Amgen3$68
Pfizer3$49
Amarin Pharma, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,265 in reported general payments places this provider in the 20th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$800,070
Medicare patients
1,992
Services billed
9,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$96,687
EntrestoSacubitril/Valsartan60$50,065
XareltoRivaroxaban17$9,472
MultaqDronedarone Hcl11$8,634
Synjardy XrEmpagliflozin/Metformin Hcl12$7,394
BrilintaTicagrelor16$6,998
BystolicNebivolol Hcl11$4,924
Ranolazine ErRanolazine24$3,503
Amiodarone Hcl18$1,886
Nitroglycerin59$1,203
Amlodipine Besylate149$553
Rosuvastatin Calcium80$507
Nifedipine ErNifedipine30$489
SotalolSotalol Hcl31$358
Carvedilol93$326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$49$96,687116 claims
NovartisEntresto$75$50,06560 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →